Introduction: Individualizing glycemic targets to goals of care and time to benefit in persons
. In older adults with diabetes, it is often unclear whether reducing glucose achieves meaningful risk reduction or prevents complications of hyperglycemia.
Aggressive glycemic control has been questioned in the frail elderly and those with limited life expectancy, and adverse effects such as hypoglycemia are of concern [3, 4] .
Despite efforts to reduce the risk of hypoglycemia in the elderly by relaxing glycemic control, there is little information on how to deprescribe, which includes reducing the dose or stopping/switching antihyperglycemic medications in order to individualize HbA1C targets. Clinicians are aware that relaxed glycemic targets may be appropriate in older patients, but they require guidance to assist with deprescribing [5] . To address this knowledge gap, we conducted a systematic review to identify studies that have evaluated the benefits and harms of deprescribing antihyperglycemics in adults with type 2 diabetes (T2DM).
METHODS
Our protocol was registered in PROSPERO (CRD42015025727). We followed PRISMA guidelines [6] . This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Data Sources and Searches

MEDLINE (1946 onward), EMBASE (1947
onward), and the Cochrane Library through to July 2015 were searched for relevant studies.
The references of relevant studies were scanned. 
Data Synthesis and Analysis
Two independent reviewers conducted risk of bias assessments for eligible studies using
Cochrane's ROBINS-I tool [7] . We conducted a narrative synthesis of results, using methods described in our registered protocol [8] . Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess quality of evidence [9] .
RESULTS
Study Selection
Our search generated 3458 titles after de-duplication. We evaluated 42 full-text articles and two articles met the eligibility criteria forqualitative synthesis [10, 11] . The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram is displayed in Fig. 1 .
Study Characteristics and Risk of Bias
The first of the controlled before-and-after studies which we identified as meeting the inclusion criteria was that of Aspinall et al.
[11] who investigated deprescribing glyburide (discontinuing glyburide and either switching to an alternative agent or not adding additional medication to the therapeutic regimen) in
American community-dwelling older adults via an educational intervention delivered to pharmacists (see Table 1 ). The second such study, by Sjöblom et al. [10] , investigated the withdrawal of all antihyperglycemics (or a reduction of insulin) versus continuing antihyperglycemics in Swedish nursing home patients. The full study characteristics are outlined in Table 1 . Both studies were judged to be at serious risk of bias for all outcomes according to ROBINS-I tool [7] due to important problems with confounding, selection of participants, and deviations from intended interventions (ESM Appendices 2, 3).
Narrative Summary of Eligible Studies
In the study by Aspinall et al. [11] , patients in the intervention group were more likely to stop CI: -0.16 to 0.12%). In addition, no significant difference was observed in the rates of Sjöblom et al. [10] reported a non-significant increase in HbA1C level for the intervention group following deprescribing (mean difference 1.10%; 95% CI 0.56% lower to 1.64% higher).
There was no significant difference in the risk of all-cause mortality for the deprescribing group compared to the control group (RR 0.74; 95% CI 0.29-1.87). A complete summary of the findings is provided in ESM Appendix 5.
Quality of Evidence
Based on the GRADE rating system, the quality of evidence for both studies was very low due to their non-randomized design and concerns surrounding the risk of bias and imprecision.
GRADE evidence tables are given in ESM Appendices 4 and 5.
DISCUSSION
Summary
Our systematic review identified two studies which assessed deprescribing antihyperglycemics in elderly patients. One trial involved a group of community-dwelling and predominantly male elderly patients with a baseline HbA1C level of approximately 7.2% [11] . Deprescribing glyburide in these patients does not appear to adversely affect glucose control, suggesting that an educational intervention aimed at pharmacists may reduce glyburide use without compromising glucose control. However, the quality of evidence of this study is very low. Although glyburide is associated with hypoglycemia and poses a higher risk than do other sulfonylureas [12] , deprescribing of glyburide does not appear to reduce hypoglycemic events.
The second trial involved patients in 17 different nursing homes in Sweden [10] . Of these patients, 75% (24/32) remained in the intervention group after 3 months, with four patients withdrawn due to hyperglycemia. The results of this study demonstrate that frail elderly patients are often treated to well below the HbA1C targets and that deprescribing is possible in the majority of patients without a large impact on HbA1C levels (increase of 0.6% after 6 months in intervention group to an HbA1C level of 5.8%). Hypoglycemic events were not reported.
These studies suggest that the deprescribing of antihyperglycemics in older people is a feasible strategy and may not compromise blood glucose control or lead to clinically significant increases in HbA1C levels, albeit the published evidence is of very low quality.
Comparison to Existing Literature
A 2015 retrospective cohort study demonstrated that deintensification of diabetes therapy is attempted in around 20-30% of patients with low HbA1C levels [13] . However, this study did not report clinical outcomes of deintensification. A 2011 retrospective analysis of predominantly male elderly patients with renal impairment (creatinine clearance\50 mL/ min) investigated the effect of switching from glyburide to glipizide (uncontrolled before-after study) [14] . Despite an increase in HbA1C level of 0.34% at 1 year, rates of hypoglycemia fell from 31 to 13%. These results suggest that hypoglycemia may be reduced following a switch to sulfonylureas with a lower risk of hypoglycemia and are consistent with meta-analysis data suggesting that glyburide carries an elevated risk of hypoglycemia compared to glipizide [12] .
Future Research
Our findings signal a need for adequately 
Strengths and Limitations
We used rigorous systematic review methodology [6, 15] and GRADE to assess the quality of evidence. However, only two studies of very low quality were identified. We found limited outcome data in the eligible studies and a lack of patient-important outcomes. The
Aspinall et al. study [11] , while large, only provides evidence related to deprescribing glyburide; and may not apply to patients on other antihyperglycemics. Neither study [10, 11] provided practical information to assist clinicians in deprescribing.
CONCLUSION
The evidence needed to guide clinicians in helping patients achieve relaxed glycemic targets through deprescribing is currently lacking. While our systematic review suggests deprescribing approaches may be feasible and safe, we found no evidence of benefit or reduced harm. Adequately powered high-quality studies of deprescribing antihyperglycemics with patient-important outcomes are required to support evidence-based decision-making. Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
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